BioWorld Asia

May 12, 2004

Arpida Raises CHF51.3M, Plans To Move Iclaprim Into Phase III

Arpida Ltd. raised CHF51.3 million (US$39.4 million) in a Series C funding round, bringing its total funding to date to CHF105 million. (BioWorld International) Read More

Faust Pharmaceuticals Closes EUR16M Second-Round Financing

Molecular Switch That Triggers Apoptosis Delivers Drug Target

Eirx Out-Licenses Apoptosis Targets To OSI In $18.8M Deal

Lectus Gets Investment From Takeda For PFD Protein Work

Report: 25 Recommendations For EU Strategies On Genetic Testing

Immatics Raises EUR8.5M In First Round Of Financing

Advanced Biotherapy Cross-Licenses IP With Innogenetics

Biota Holdings Suing GSK Over Support For Flu Drug

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for March 13, 2026.

Tanycytes in green capturing tau protein in red.

Brain’s hidden tau-clearing pathway uncovered

BioWorld Science

Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...

News in brief

BioWorld Asia

BioWorld Asia briefs for March 10, 2026

MSD synthesizes α-synuclein PET agents

BioWorld Science

Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...

Muscarinic M4 receptor positive allosteric modulators described in Neurosterix patent

BioWorld Science

Neurosterix Pharma Sarl has divulged 3-cyclopropylpyrazole derivatives acting as muscarinic M4 receptor positive allosteric modulators. They are reported to be...